Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers by Michaeli, B.
UNIVERSITÉ DE LAUSANNE - FACULTÉ DE BIOLOGIE ET DE MÉDECINE 
Service de Médecine Intensive Adulte 
Chef de service : Professeur René Chioléro 
Effects of fish oil on the neuro-endocrine responses 
to an endotoxin challenge in healthy volunteers 
THESE 
présentée à la Faculté de biologie et de médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
par 
Burkhard MICHAEL! 
Médecin diplômé de la Bundesrepublik Deutschland 
et reconnu par la Confédération Suisse 
Originaire de Saarbrücken (D) 
Lausanne 
2007 
Résumé 
Introduction et hypothèse : Certains acides gras polyinsaturés de type n-3 PUFA, qui sont 
contenus dans l'huile de poisson, exercent des effets non-énergétiques (fluidité des membranes 
cellulaires, métabolisme énergétique et prostanoïdes, régulation génique de la réponse 
inflammatoire). Les mécanismes de la modulation de cette dernière sont encore mal connus. 
L'administration d'endotoxine (LPS) induit chez les volontaires sains une affection inflammatoire 
aiguë, comparable à un état grippal, associé à des modifications métaboliques et inflammatoires 
transitoires, similaires au sepsis. Ce modèle est utilisé de longue date pour l'investigation clinique 
expérimentale. 
Cette étude examine les effets d'une supplémentation orale d'huile de poisson sur la réponse 
inflammatoire (systémique et endocrinienne) de sujets sains soumis à une injection d'endotoxine. 
L'hypothèse était que la supplémentation d'huile de poisson réduirait les réponses physiologiques 
à l'endotoxine. 
Méthodes : Quinze volontaires masculins (âge 26.0±3.1 ans) ont participé à une étude 
randomisée, contrôlée. Les sujets sont désignés au hasard à recevoir ou non une 
supplémentation orale : 7.2 g d'huile de poisson par jour correspondant à un apport de 1.1 g/jour 
d'acides gras 20:5 (n-3, acide écosapentaénoïque) et O. 7 g/jour de 22:6 (n-3, acide 
docosahexaénoïq ue). 
Chaque sujet est investigué deux fois dans des conditions identiques : une fois il reçoit une 
injection de 2 ng par kg poids corporel de LPS intraveineuse, l'autre fois une injection de placebo. 
Les variables suivantes sont relevées avant l'intervention et durant les 360 min qui suivent 
l'injection : signes vitaux, dépense énergétique (EE) et utilisation nette des substrats (calorimétrie 
indirecte, cinétique du glucose (isotopes stables), taux plasmatique des triglycérides et FFA, du 
glucose, ainsi que des cytokines et hormones de stress (ACTH, cortisol, Adré, Nor-Adré). 
Analyses et statistiques: moyennes, déviations standards, analyse de variance (one way, test 
de Scheffé), différences significatives entre les groupes pour une valeur de p < 0.05. 
Résultats : L'injection de LPS provoque une augmentation de la température, de la fréquence 
cardiaque, de la dépense d'énergie et de l'oxydation nette des lipides. On observe une élévation 
des taux plasmatiques de TNF-a et IL-6, de la glycémie, ainsi qu'une élévation transitoire des 
concentrations plasmatiques des hormones de stress ACTH, cortisol, adrénaline et noradrénaline. 
L'huile de poisson atténue significativement la fièvre, la réponse neuro-endocrinienne (ACTH et 
cortisol) et sympathique (baisse de la noradrénaline plasmatique). Par contre, les taux des 
cytokines ne sont pas influencés par la supplémentation d'huile de poisson. 
Conclusion : La supplémentation d'huile de poisson atténue la réponse physiologique à 
l'endotoxine chez le sujet sain, en particulier la fièvre et la réponse endocrinienne, sans influencer 
la production des cytokines. Ces résultats soutiennent l'hypothèse que les effets bénéfiques de 
l'huile de poisson sont principalement caractérisés au niveau du système nerveux central, par des 
mécanismes non-inflammatoires qui restent encore à élucider. 
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Summary 
Background Et aims: Fish oil (FO) has been shown to modulate the acute and chronic 
inflammatory responses. Endotoxin (LPS) has been shown to mimic several aspects of 
sepsis. The study aimed at testing the effects of oral FO supplements in healthy subjects 
submitted to intravenous LPS on systemic and endocrine response. 
Subjects and methods: Fifteen healthy men (aged 26.0± 3.1 years, BMI 23.8± 1.9 kg/m2 ), 
were enrolled. Subjects were randomised to 3-4 weeks of oral FO supplementation (7.2 g/ 
day, providing 1.1 g/day of 20:5(n·3) and 0.7 g/day of 22:6 (n-3) fatty acids) or no 
supplementation and then submitted to endotoxin challenge: 2 ng/kg of LPS. Ali subjects 
were studied twice (placebo and LPS). Measurements: vital signs, energy expenditure (EE), 
glucose and lipid metabolism (2H2-glucose), plasma cytokines and stress hormones for 6 h 
after LPS or placebo. 
Results: LPS caused cytokine release, fever, increases in heart rate, resting EE and 
substrate oxidation, plasma glucagon and glucose concentrations; the neuro·endocrine 
response was characterised by increased plasma stress hormones. FO significantly blunted 
fever, ACTH and cortisol plasma levels (no effect on cytokine release). FO blunted the peak 
norepinephrine after LPS. 
Conclusion: FO supplements blunted the endocrine stress response and the increase in 
body temperature, but had no impact on cytokine production after LPS. These findings 
conflict with the postulated anti·intlammatory effects of FO on arachidonic acid 
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metabolism and cytokine release. These results suggest that FO may exert beneficial 
effects in sepsis though non-inflammatory which require further investigations 
© 2006 Elsevier Ltd and European Society for Clinicat Nutrition and Metabolism. All rights 
reserved. 
Introduction 
Fatty acids constitute an important source of endogenous 
and exogenous energy, providing usually 30-45% of daily 
energy supply. Among them, two families are particularly 
important for human health, the n-6 and the n-3 poly-
unsaturated fatty acids (n-6 PUFAs and n-3 PUFAs). The n-6 
PUFA linoleic acid is found in substantial amounts in 
vegetable seeds and oils and is the precursor of arachidonic 
acid. Sorne n-3 PUFA are also found in vegetable seeds and 
oil, but the main active of these compounds, docosahex-
aenoic acid (DHA, 20:5 (n-3)) and ecospentaenoic acid (EPA, 
22:6 (n-3)) are essentially found in marine products and fish 
oils (FO). 
N-3 and n-6 PUFAs are actively incorporated into cell 
membrane phospholipids and modify the membrane physical 
and chemical characteristics. 1' 2 They exert numerous 
biological effects, influencing metabolic pathways and 
numerous cell functions. They have also been shown to 
modulate the acute and chronic inflammatory processes and 
to exert anti-inflammatory properties both in vitro in 
vivo-white n-6 PUFAs upregulate the inflammatory pro-
cesses. The mechanisms of the anti-inflammatory effect of 
n-3 PUFAs are complex, including changes in membrane 
fluidity, synthesis of lipid mediators, cytokine production, 
inflammatory gene expression and remain yet not fully 
understood. 3,4 Recent in vivo and in vitro studies suggest 
that n-3 PUFAs may decrease the inflammatory response to 
both acute and chronic inflammatory diseases. 5 12 
lntravenous endotoxin (LPS) induces a reproducible and 
transient inflammatory condition in animals and healthy 
humans, which mimics several aspects of sepsis. 13 This 
healthy subject model was used in the present study to test 
the hypothesis that oral FO supplementation attenuates the 
physiologie response to intravenous endotoxin in healthy 
subjects, particularly the inflammatory response. 
Subjects and methods 
Sixteen healthy males were enrolled. All had a normal body 
weight, with no metabolic or endocrine disease, or medica-
tion. They all underwent thorough clinicat evaluation 
of their cardiopulmonary status and had an ECG recor-
ding during an inclusion visit. Mean age was 26.0 years 
(±3.1), mean body weight 75.3±7.3kg, and mean BMI 
23.8± 1.9 kg/m2• 
Experimental protocol 
The study was conducted with lnstitutional Ethical commit-
tee approval and individual written informed consent. The 
experiments were performed under the supervision of 
critical care physicians. 
Sixteen subjects were randomised to an intravenous LPS-
challenge atone (n = 8) or to an intravenous LPS-challenge 
preceded by 3-4 weeks oral FO supplementation (n = 8) 
(7.2 g/day of OMEGA-3 Gisand® containing 17% EPA, 11% 
DHA). Each subject was studied twice: placebo and LPS-
challenge were separated by 1 week at least and in a 
random order. One subject of the FO group interrupted the 
research protocol. The subjects came to the metabolic 
laboratory at 7 AM after an overnight fast. Upon arrivai, they 
were requested to void and urine was discarded. Thereafter, 
they remained supine quietly in a bed for the next 10 h. An 
antecubital vein was cannulated for labelled glucose and 
lactate infusion. A dorsal hand vein of the opposite arm was 
cannulated to sample partially arterialised blood samples 
(infrared heating of the hand). 14 
After blood sampling for determination of basal glucose 
isotope enrichment and basal lactate, a primed continuous 
infusion of 6,6 2H2 glucose was infused (Cambridge Isotope 
Laboratory, Cambridge, MA; prime 3 mg/kg/min, continuous 
30 µg/kg/min) from T-180 (180 min before intravenous LPS) 
throughout the study. After 2.5 h of tracer equilibration, 
blood samples were collected at a 30-min interval until the 
end of test. ln addition, 13C-labelled lactate at 0.03% excess 
(10 µmol/kg/min) was infused from T-90 until T270. Sys-
temic lactate kinetics (lactate clearance and endogenous 
production) were assessed by means of a modified Connor's 
method. 15 Breath samples were collected every 30 min into 
10 ml hexatainers (Europa Scientific Crew, UK) in quadru-
plate to determine 13C02 excretion (as reflect of lactate use 
as metabolic substrate). Glucose turnover (6,6 2Hz-glucose) 
and lactate conversion into glucose (13C-glucose) were 
measured at the same time points. 
Endotoxin challenge: endotoxin 2 ng/kg, (Escherichia 
coti, USP Rockville, MD) or placebo (NaCl O. 9%) was 
administered as intravenous bolus at time TO. Heart rate, 
blood pressure, and respiratory rates were continuously 
monitored throughout the experimental protocol. ln addi-
tion, the studies were performed in a metabolic laboratory 
located within the intensive care unit and under the 
supervision of a trained intensive care physicians. 
The data concerning the metabolic, inflammatory and 
neuro-endocrine response in a LPS-challenge are reported in 
the present paper, white those of lactate and glucose 
metabolism will be reported separately. 
Measurements 
Blood was sampled at regular intervals to determine 
glucose, triglycerides, FFA, hormone levels (insulin, gluca-
gon, cortisol, ACTH, norepinephrine, epinephrine), and 
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inflammatory markers (TNF-o:, IL-6, C-reactive protein). 
Blood samples were collected into heparinised tubes and 
centrifuged to separate plasma. Plasma was stored at -20 
and -80 °C until analysis. Urine was sampled from sponta-
neous voiding throughout the study to assess the urinary 
nitrogen excretion (see "analytical procedures"). 
The following vital functions were monitored: heart rate, 
rectal temperature (Hellige, Servomed), non-invasive arter-
ial blood pressure, cardiac output by bioimpedance 
(NCCOM3 cardiodynamic monitor, BoMed, lrvine CA), re-
spiratory rate, oxygen saturation (Ohmeda, Biox 3740 Pulse 
oximeter). 
Resting energy expenditure (EE) and substrate 
metabolism 
Indirect calorimetry was performed throughout the study. 
Oxygen consumption (V 0,) and C02 production (V co,) 
measured by indirect calorimetry, using a homemade 
calorimeter, 16 were used to determine the EE. 17 
Rates of glucose appearance and disappearance were 
calculated from plasma 6,6 2H2 glucose enrichments. Whole 
body glucose turnover was calculated with Steele's equation 
for non-steady-state conditions 18 : 
R _ F -p · Vd(C2 + C1)/2 · (IE2 - IE1)/M 
a- (IE2+IE1)/2 ' 
Rd= Ra - p · Vd · (C2 - C1)/M, 
where F is the infusion rate of labelled glucose; C the 
glucose concentration; IE the isotopie enrichment; a pool 
fraction (p) of O. 75 and a distribution volume for glucose 
(Vd) of 0.2 l per kg body weight were used for these 
calculations. 
Non-oxidative glucose utilisation was calculated as the 
difference of Rct(glucose) and the net oxidation of carbohy-
drates calculated from indirect calorimetry. 
Analytical procedures 
Substrate analysis 
Plasma glucose concentrations were measured enzymati-
cally using a Yellow Spring Instrument YSI 2300 STAT PLUS 
(Yellow Spring, OH, USA); Plasma free fatty acid concentra-
tions were measured with a colorimetric method, using a kit 
from Wako (Freiburg, Germany). Triglycerides levels were 
analysed enzymatically using the PAP 150 test (BioMérieux, 
France). The urine nitrogen excretion rate was determined 
with the micro-Kjehldahl method. 
Concentrations of adrenocorticotropine (ACTH) were 
determined with a chemiluminescence assay kit (Nichols 
lnstitute Diagnostics, San Juan Capistrano, CA). Concentra-
tions of insulin (kit from Adaltis, Casalecchio di Reno, ltaly), 
cortisol (kit from Diagnostic Products Corporation, Los 
Angeles, CA) and glucagon (kit from Linco Research, St. 
Charles, MO) were determined by radioimmunoassay. 19 
Plasma concentrations of bioactive IL-6 and TNF-o: were 
determined using bioassays as previously described (7TD1 IL-
6-dependent mouse-mouse hybridoma cells20; WEHI 164 
B. Michaeli et al. 
clone 13 cell line). 21 CRP was analysed by turbidimetry on a 
Hitachi 917 (Roche) using reactants produced by DaKo. 
Plasma catecholamines were determined by HPLC with 
electrochemical detection. 22 
Plasma glucose isotopie enrichments were determined on 
deproteinised samples partially purified over sequential 
cation-anion exchange resins (AG 1 -X8 and AG 50W-X8; 
Bio-Rad, Richmond, CA). For glucose measurements, penta-
acetyl glucose was analysed with gas chromatography-mass 
spectrometry (Hewlett Packard, Palo Alto, CA). 
Statistical analysis 
The data are expressed as mean ± SD. Comparisons between 
groups were carried out with one-way analysis of variance, 
and post-hoc comparisons with Scheffé tests. Variables 
measured repeatedly were compared by two-way analysis 
of variance for the effect of group and time, and their 
interaction. Post-hoc comparisons were made by Scheffe 
tests for the effect of group, Dunett's test for the effect of 
time. P<0.05 was considered statistically significant. 
Statistical analysis was performed using JMP Statistical 
software version 3.2.2 (SAS lnstitute, Cary, NC). 
Results 
Physiologie effects of endotoxin 
lntravenous LPS induced flu-like symptoms after 75 min in all 
subjects; they were associated with significant systemic, 
endocrine and metabolic changes (Table 1 ). All subjects 
complained about headache, muscle ache and nausea; 
vomiting was observed in two subjects, without any other 
serious side effect. 
There was a marked increase in heart rate (+38min-1) 
and cardiac output (+34%; Fig. 1A), and in body tempera-
ture (maximum + 1.7 °C; Fig. 1B), white mean blood pressure 
and peripheral oxygen saturation did not change signifi-
cantly. 
Pro-inflammatory cytokines (TNF-o: and IL-6) were not 
detectable at baseline, and increased sharply after LPS 
(Fig. 2). The endocrine response was substantial: plasma 
ACTH, cortisol levels, norepinephrine (NE +100%) and 
epinephrine (EPI +250%) increased strongly after LPS 
(Fig. 3). Plasma CRP was not detectable at baseline and 
increased 8 h after LPS-injection, ranging between 6 and 
21 mg/l. 
Sustained increases in EE (max. +40%) were observed 
after LPS. Plasma glucose showed a biphasic pattern, with a 
transient decrease at T120 (-8%) and moderate increase 
thereafter (T180+10%). lnsulin levels were unchanged, white 
glucagon levels peaked at T240 (+71%). Net glucose 
oxidation decreased continuously (-45% by the end of the 
protocol). Both plasma free fatty acids and net fat oxidation 
were markedly increased after LPS (+94%) (Table 1 ). 
Effect of FO 
FO did not influence the basal physiological variables, nor 
the inflammatory response to LPS (TNF-o:, IL-6, and CRP) 
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Table 1 Effects of physiologie changes due to LPS in fish oil treated (3-4 weeks oral FO supplementation) and control group 
(no FO). 
Time (min); LPS injection at TO TO T90 
Energy expenditure EE (kcal/min) 
Control 1.25±0.13 1.53±0.29a 
Fish oil 1.34±0.17 1.69±0.26a 
Respiratory quotient 
Control 0.82±0.06 0.80±0.06 
Fish oil 0.80±0.04 0.81 ±0.03 
Glycemia (mg/dl) 
Control 94±6 88±4a 
Fish oil 96±10 86±9a 
Free fatty acids (mEq/l) 
Control 0.38±0.20 0.36±0.23 
Fish oil 0.33±0.21 0.43±0.27 
Net glucose oxidation (mg/min) 
Control 105±63 114± 75 
Fish oil 96±50 148±48a 
Net fat oxidation (mg/min) 
Control 69±30 94±37a 
Fish oil 77±25 93±32 
lnsulin (mU/l) 
Control 9.0±2.5 
Fish oil 10.8±3.9 
Glucagon (ng/l) 
Control 63±13 
Fish oil 69±13 
Data as mean ± SD 
aDifference significant from baseline (TO). 
bDifference significant between groups. 
(Fig. 2). By contrast FO attenuated other important aspects 
of the physiological response to LPS. Body temperature was 
Lower in the treated subjects from T240 (P = 0.012; Fig. 1 B), 
white the cardiovascular response was not modified. The 
sympathoadrenal and adrenocortical responses to LPS were 
blunted by FO. White the basal levels of plasma ACTH and 
cortisol were similar, peak ACTH was decreased by 50% by FO 
(P = 0.028), and peak cortisol Level was 30-40% lower in the 
treated group (P = 0.002, Fig. 3A). Peak NE Level after LPS 
was 45% Lower in the FO group (P = 0.01 ). Basal levels of 
plasma EPI did not differ. The EPI response to LPS was 
blunted in subjects treated with FO (trend: P = 0.08) 
(Fig. 3B). 
FO supplementation did not influence the metabolic 
response to LPS: plasma glucose and FFA levels, glucose 
turnover and substrate net oxidation (glucose and FFA) were 
similar in both the groups (Table 1 ). 
Discussion 
To our knowledge, our study is the first human study testing 
the modulating effects of FO in healthy subjects submitted 
T120 T180 T240 T360 
1.56±0.36a 1.75±0.40a 1.64±0.31a 1.53±0.25a 
1.68±0.zoa 1.83±0.34a 1.79±0.27a 1.62±0.24a 
0.76±0.063 'b 0.77±0.04a 0.75±0.05a 0.77±0.03a 
0.80±0.06b 0.77±0.04a 0.76±0.04a 0.77±0.03a 
87±4a 103±9a 102±8a 107±11a 
88±9a 103±9a 103±6a 106±8a 
0.58±0.37a 0.69±0.30a 0.84±0.31a 1.07 ±0.14a,b 
0.51 ±0.23a 0.67±0.22a 0.78±0.19a 0.85±0.15a,b 
60±88"'b 90±56 51 ±77a 73±37 
122±91b 84±54 59±60 76±40 
119±42a 132±38a 134±39a 113±24a 
101 ±39a 132±52a 137±41a 113±2?3 
7.1±1.6 10.2±3.5 8.4±2.9 
6.9±1.1a 9.6±3.5 8.6±1.6 
91±23a 108±20a 99±19a 
101 ±34a 103±47a 85±18a 
to an endotoxin challenge. FO decreased fever and blunted 
the neuro-endocrine response but had neither influence on 
the metabolic, nor on the inflammatory responses. 
Effect of endotoxin 
The general effects of experimental endotoxemia in man 
were first described in 1967, being characterised by a 
transient systemic inflammatory reaction. 23 Afterwards, the 
metabolic and endocrine effects of endotoxin were de-
scribed24·25 and the intravenous injection of endotoxin 
became a widely used experimental model. 26 ln the present 
study 2 ng/kg was injected, as doses 2--4 ng/kg of LPS have 
been given to healthy humans on several occasions by other 
investigators, without any major adverse effect. 13 •27 
Endotoxin is the common name for lipopolysaccharides, 
which are present in the outer cell wall of Gram-negative 
bacteria. lntravenous LPS elicits a transient self·limited 
flue-like state, associated with a short-lived release of 
proinflammatory and anti-inflammatory cytokines and 
other mediators. A full neuro-endocrine response is 
observed, involving the hypothalamo-pituitary-adrenal 
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Figure 1 Systemic responses to endotoxin: (A) heart rate and cardiac output, (B) temperature. 
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Figure 2 Effects of FO on plasma TNF-a and IL-6 after a LPS challenge. 
axis (HPA) and the sympathoadrenal systems. This response 
is associated with cardiovascular, coagulation and meta-
bolic changes, as well as alterations of endothelial 
functions. 27 
ln the present study, an intravenous endotoxin challenge 
was applied after 3--4 weeks oral FO supplementation in 
healthy subjects. As expected, a full inflammatory response 
was observed after LPS. 
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Figure 3 Effects of FO on the endocrine responses to LPS. 
Body temperature and neuro-endocrine response 
Fever is a non-specific response mediated by complex 
peripheral and central mechanisms, involving prostaglandin 
E2, a metabolite of arachidonic acid, produced in response 
to cytokines and other mediators of inflammation. 28 The 
ability of short n-3 FO supplementation to inhibit the 
pyrogenic effects of intraperitoneally IL-1 was first demon-
strated in rats. 29 After prolonged supplementation, fever 
was also reduced after intracerebrovascular IL-1, suggesting 
the existence of two distinct mechanisms by which FO 
modulates the thermoregulation. This antipyretic effect of 
FO was also documented in healthy humans subjected to the 
intramuscular injection of a typhoid vaccine. 30 Our present 
results fully corroborate these observations: the full blow 
pyrogenic response observed in the contrais, was blunted in 
the FO subjects. 
The HPA and the systemic sympathetic system are the two 
main peripheral limbs of the stress system. The classical 
stress reaction is elicited by pro-inflammatory cytokines, by 
the release of hypothalamic hormones (corticotropin, 
vasopressin) or by the direct activation of the central 
systemic sympathetic system. 31 Many stimuli can elicit 
stress response including tissue injury, infection, surgery, 
mental and psychological factors, and hypoglycemia. Our 
results suggest the central component of the stress response 
was modulated by FO supplementation. ln support of this 
hypothesis, it has been documented that dietary FO 
significantly affects the fatty acid profile in the CNS cells 
(Y. Carpentier: persona! communication). Animal and human 
studies have reported the potential of FO to reduce the 
stress response. ln rats submitted to intracerebroventricular 
administration of corticotropin or fear-conditioned beha-
viour, DHA significantly reduced this response. 32 ln medical 
students submitted to psychological tests during the exam 
period, DHA reduced the hostility reactions and decreased 
norepinephrine plasma levels, while hostility increased in 
the contrai group33 ; cortisol levels were unchanged. ln 
another study assessing 9 weeks DHA of supplementation in 
students under exam-stress, 34 a 30% reduction of norepi-
nephrine plasma levels was observed. ln healthy subjects 
submitted to mental stress, 3-4 weeks FO supplementation 
blunted the neuro-endocrine, metabolic and cardiovascular 
responses to stress. 35 These data combined with ours show 
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that FO blunts the neuro-endocrine response to various 
types of stress. The central sympathetic effect seems to be 
more important than the peripheral, as suggested by the 
larger suppression of plasma norepinephrine compared to 
epinephrine. Based on these results, we hypothesize that 
oral FO modulated the stress response to LPS in our subjects, 
by a central nervous mechanism, which might open new 
potential therapeutic perspectives. 
lnflammatory response 
Oral intake of FO in humans is reported to be beneficial in 
chronic and acute inflammatory conditions, but the 
mechanism is not well elucidated. ln many in vitro and in 
vivo animal experiments, FO was associated with a reduc-
tion of pro-inflammatory cytokines release. 13 The classical 
explanation of this effect is linked to the incorporation of 
n-3 PUFAs into cell membranes of immune competent cells, 
resulting in a lower production of proinflammatory inter-
leukins. 36 FO has been shown to reduce mononuclear IL-1 
production, 5 depress the immune response in bacteremic 
pigs, 6 and to blunt cytokine production in burned rats. 7 ln 
critically ill humans with severe sepsis, intravenous FO 
reduced ex vivo cytokine release by monocytes in response 
to LPS. 37 
Surprisingly, although we observed a marked increase in 
IL-6 and TNF-a in our subjects, cytokine release was not 
significantly influenced by FO supplementation suggesting 
that FO did not act primarily by down regulating cytokines 
release. Similar observation was reported in healthy humans 
after an intramuscular injection of typhoid vaccine: prior 
supplementation with FO failed to blunt the response of 
TNF-a (although, in contrast to our present observation, it 
significantly reduced IL 1 and IL6 concentrations). 30 lt 
remains nonetheless possible that FO specifically down-
regulates other pro-inflammatory cytokines which were not 
monitored in this study. The increase in CRP was modest and 
not influenced by FO administration. CRP was determined 
8 h after LPS injection, when CRP production was only 
submaximal; in addition, CRP was not measured by means of 
a high-sensitivity method, which may have limited detection 
of early changes. Further study is required to determine 
if FO donwnregulates the acute phase proteins response 
after LPS. 
Limitations in the study design may also provide some 
explanation for our results. Dose and duration of oral FO 
supplementation is controversial. We used a 3-4 week FO 
supplementation protocol providing about 2 g DHA and EPA 
per day. According to the published data this should result in 
significant membrane incorporation of n-3 PUFAs. Although 
we did not measure the membrane incorporation of n-3 
PUFAs, it seems unlikely that this duration was insufficient to 
achieve the expected changes, as demonstrated by the 
effects on fever and endocrine response. ln monks sub-
mitted to an endotoxin challenge after a prolonged FO 
supplementation (26-52 weeks supplementation) similar 
cytokine results were reported. 38 Altogether, these results 
suggest that FO does not exert a major effect on 
the inflammatory response to LPS, a very short-lived 
inflammation. 
B. Michaeli et al. 
Metabolic response 
The effects of FO on glucose metabolism have been 
extensively studied although conclusions of these studies 
remain disputed. Numerous observations show that FO does 
not alter basal glucose production or basal glycaemia in 
healthy individuals. lt has also been observed that FO may 
enhance gluconeogenesis, and that such effect may be 
detrimental in insulin-resistant obese or diabetic patients. 39 
Our results clearly show that FO does not affect energy 
metabolism and substrate utilisation in healthy subjects 
submitted to LPS. Based on the simultaneous decrease on 
plasma catecholamines, hypothalamo-pituitary axis, and 
body temperature, it is tempting to speculate that FO 
exerted its main effect at the level of the central nervous 
system, whereas disturbed glucose homeostasis related to 
the peripheral effects of endotoxin were not affected by FO. 
Further studies are required to better define the mechan-
isms of actions of FO and the clinicat perspective in term of 
patient's care. 
Conclusion 
Three to four weeks of oral FO supplementation blunts 
important aspects of the response to intravenous LPS in 
healthy subjects: fever, central sympathetic and hypotha-
lamo-pituitary-adrenal response are blunted. By contrast 
the inflammatory cytokine response was not affected. 
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